Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Melflufen + Dexamethasone vs Pomalidomide + Dexamethasone in Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma
2016-003517-95Phase 3Completed
- Sponsor
- Oncopeptides AB
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Melflufen + dexamethasone with Pomalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Dec 2016; status: completed.
02
Drugs
melphalan flufenamidepomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-003517-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003517-95.